CECharles R. Esther

Charles R. Esther

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charles R. Esther has a total of 361 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bronchial segmental heterogeneity of responsiveness to modulator therapy in cystic fibrosis: linking structural improvements on CT to Inflammation in Bronchoalveolar lavage fluid

    by Ieva Aliukonyte, Samantha L. Durfey, Siddhartha G. Kapnadak, Mary E. Teresi, Tahuanty Pena, Punitkumar Makani, Eleni-Rosalina Andrinopoulou, Raul A. Villacreses, John P. Clancy, Charles R. Esther, et al.

    Background: Although Elexacaftor–tezacaftor–ivacaftor (ETI) improves lung function and reduces exacerbations in cystic fibrosis (CF), airway inflammation and bronchial wall thickening do not completely resolve. Characterizing regional heterogeneity in bronchial wall thickness before and after ETI may provide insight into residual disease. We investigated whether bronchial wall thickening during ETI reflects ongoing inflammation, mucus burden, and infection at the segmental level. Methods: In this prospective observational cohort study, paired pre-ETI and 1.5-year post-ETI chest CT scans and bronchoalveolar lavage (BAL) samples were analyzed from five preselected lung segments in nine adults with CF. An AI-based pipeline generated automated segmental bronchus–artery metrics, including bronchial wall area (B wa /B oa ), wall thickness (B wt /A), inner diameter (B in /A), and outer diameter (B out /A) ratios, as well as mucus plug number and volume. These metrics were correlated with segment-matched BAL markers of inflammation, mucus burden, and Pseudomonas aeruginosa infection. Results: Responses to ETI were heterogeneous both between and within subjects. Across 176 segments, 91.3% ( sd 19.1) showed reductions in B wa /B oa , 86.7% ( sd 18.4) reductions in B wt /A, and 77.1% ( sd 20.9) increases in B in /A, whereas B out /A remained stable. However, differences in the magnitude of these changes were observed at the segmental level within subjects. Pre-ETI, bronchial wall thickness was most strongly associated with neutrophil elastase. Post-ETI, this association weakened but persisted, while sialic acid emerged as an additional predictor of residual wall thickness. P. aeruginosa burden was also associated with wall thickness post-ETI but explained less of the variance than inflammatory and mucus markers. Conclusions: ETI produces significant but variable improvements at the segmental level in bronchial dimensions. Persistent segmental heterogeneity suggests that local inflammation, mucus retention, and infection continue to shape residual structural lung disease. Automated segmental CT analysis may enable more individualized monitoring and management in the era of CFTR modulation.

  • Influence of inflammation on drug transporter expression in human airway epithelia: Implications for inhaled drug pharmacokinetics

    by Charles R. Esther, John K. Fallon, Deborah M. Cholon, Susan E. Boyles, Allison B. Williams, Hiroaki Murano, Kenichi Okuda, Jacqueline B. Tiley, Ming-Liang Tan, Liang Zhao, et al.

  • Modeling lung transporters and their influence on inhaled drug disposition

    by Shekhar Yeshwante, Ramya Mahadevan, Olagoke Sule, Jacqueline B. Tiley, Courtney L. Luterbach, Sean McCann, John K. Fallon, Philip C. Smith, Ming-Liang Tan, Ross Walenga, et al.


  • STAT3-Dependent Regulation of CFTR and Ciliogenesis Is Essential for Mucociliary Clearance and Innate Airway Defense in Hyper-IgE Syndrome

    by Ling Sun, Samantha A. Walls, Hong Dang, Nancy L. Quinney, Patrick R. Sears, Taraneh Sadritabrizi, Koichi Hasegawa, Kenichi Okuda, Takanori Asakura, Xiuya Chang, et al.

    Rationale: Hyper-IgE syndrome (STAT3-HIES), also known as Job’s syndrome, is a rare immunodeficiency disease typically caused by dominant-negative STAT3 mutations. STAT3-HIES is characterized by chronic pulmonary infection and inflammation, suggesting impaired innate host defense. Objectives: To identify airway epithelial host defense defects caused by STAT3 mutations that, together with immune dysfunction, contribute to recurrent pulmonary infections in STAT3-HIES. Methods: STAT3-HIES sputum was analyzed for biochemical and biophysical properties. STAT3-HIES excised lungs were harvested for histology, and bronchial brush samples were collected for RNA sequencing and in vitro culture. A STAT3-HIES–specific R382W mutation, expressed via lentivirus, and STAT3 knockout (CRISPR/Cas9) were studied in normal human bronchial epithelial cells under basal or inflammatory (IL1β)-stimulated conditions. Effects of STAT3 deficiency on transcriptomics, epithelial ion channel, secretory, antimicrobial, and ciliary functions were assessed. Measurements and Main Results: STAT3-HIES sputum showed increased mucus concentration and viscoelasticity. STAT3-HIES excised lungs exhibited mucus obstruction and elevated IL1β expression. STAT3 mutations reduced CFTR mRNA and protein amounts, impaired CFTR-dependent fluid and mucin secretion, suppressed antimicrobial peptide, cytokine, and chemokine expression, and acidified airway surface liquid at baseline and after IL1β exposure. Notably, mutant STAT3 suppressed IL1R1 expression. Furthermore, STAT3 mutations impaired multiciliogenesis by blocking commitment to ciliated cell lineages through inhibition of HES6, leading to defective mucociliary transport. Administration of a γ-secretase inhibitor restored HES6 expression and improved ciliogenesis in STAT3 R382W mutant cells. Conclusions: STAT3 dysfunction leads to multicomponent defects in airway epithelial innate defense, which, in conjunction with immune deficiency, contributes to chronic pulmonary infection in STAT3-HIES.


  • Open Access

    Early life elevations of methionine oxidation and ornithine track and predict cystic fibrosis structural lung disease

    by Sarah Mansour, Lisa J.M. Slimmen, George L. Silva, Genoah L. Collins, Vincent D. Giacalone, Camilla Margaroli, Badies H.A.N. Manai, David Mager, Silvia C. Estevão, Susan O. Kim, et al.

    Introduction: Early cystic fibrosis (CF) lung disease monitoring is crucial for understanding responses to therapy and preventing progressive pulmonary decline. Structural lung disease (SLD) is a major cause of pulmonary decline in CF. We aimed to identify metabolites in CF bronchoalveolar lavage (BAL) associated with and predictive of SLD. Methods: We applied untargeted metabolomics to 84 BAL samples from a cross-sectional cohort of 67 clinically stable children with CF aged 1–5 years across two sites. We used a linear mixed-effects model to select metabolites associated with SLD, BAL neutrophils, and myeloperoxidase (MPO) and neutrophil elastase (NE) activities. An independent longitudinal cohort of infants who either did or did not exhibit bronchiectasis by age 9 years was analysed to determine whether metabolites associated with SLD could also predict future lung disease. Results: In the cross-sectional cohort, 10 BAL metabolites, including methionine sulfoxide (MetO), ornithine and N -acetylmethionine (NAcMet), were associated with SLD, neutrophils, MPO and NE. The percentage of methionine oxidation (%OxMet) and the arginine–ornithine ratio were also associated with these outcomes. In the longitudinal cohort, MetO, %OxMet, ornithine and NAcMet predicted bronchiectasis development, and MetO plus ornithine was a more sensitive predictor than either alone. At age 0–2 years, these metabolites outperformed established biomarkers such as NE, MPO and interleukin-8. Conclusions: We identified BAL metabolites associated with SLD, MPO and NE, detectable in the earliest stages of CF. MetO, %OxMet, NAcMet and ornithine predicted bronchiectasis development, outperforming established biomarkers. These metabolites reflect oxidising, proteolytic and other enzymatic activities of neutrophils, highlighting potential therapeutic avenues.

  • Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis

    by Cindy L. Williams, Joanna Billings, Harriet McGowan, Rebecca McDevitt, Charles R. Esther, Cameron J. McKinzie, William S. Wilson, Charissa W. Kam

    Background: Cystic fibrosis (CF) is a multisystem disease characterized by persistent lung infection. Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) improves respiratory‐related quality of life and reduces rates of infection and antibiotic treatments. Reduced antibiotic use may alter bacterial drug resistance patterns.Methods: This was a single center, retrospective, observational study analyzing respiratory cultures obtained from people with CF (pwCF) before and after starting ETI therapy. Antibiotic courses and culture data, including susceptibilities, were obtained from the electronic medical record.Results: There were 312 pwCF on ETI included, with an average age at ETI initiation of 20.9 ± 12.0 years and an average length of time on ETI 2.48 ± 0.69 years. Compared to the pre‐ETI period, pwCF post‐ETI had reductions in the number of antibiotic courses per year (2.5 to 0.7, p < 0.001), antibiotics utilized per course (1.4 to 1.0, p < 0.001), and percentage of courses including intravenous antibiotics (59% to 38%, p < 0.001). The fraction of pwCF with at least one culture positive for Pseudomonas aeruginosa, Burkholderia species, or Stenotrophomonas maltophilia decreased after ETI initiation, though changes were not significant for Staphylococcus aureus. Antibacterial resistance patterns were similar for most antibiotics in pre‐ and post‐ETI periods, with P. aeruginosa exhibiting more resistance to fluoroquinolones post‐ETI. Individuals with resistant organisms pre‐ETI were less likely to clear the pathogen post‐ETI.Conclusion: Treatment with ETI significantly decreased antibiotic utilization and the prevalence of gram‐negative organisms. Although fewer antibiotics were used, antibiotic resistance remained unchanged or even increased post‐ETI due largely to the greater persistence of resistant organisms.


  • Open Access

    Mapping Pediatric Pulmonary Milestones 2.0 to Entrustable Professional Activities

    by Erica L. Stevens, Laura E. Chiel, Melanie S. Collins, Jennifer A. Rama, Charles R. Esther, Kristen Richard, Benjamin A. Nelson, Pnina Weiss, Brenda Nuncio, David A. Turner, et al.

  • Process and validity of linking cystic fibrosis patient registry with national Medicaid databases

    by Charles R. Esther, Melanie Rua, Haoqian Chen, Elizabeth Cromwell, Soko Setoguchi

  • Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor

    by Richard De Vuyst, Charissa W. Kam, Cameron J. McKinzie, Charles R. Esther


  • Open Access

    Medication Utilization and Lung Function Changes after Initiation of Treatment with Elexacaftor/Tezacaftor/Ivacaftor

    by Richard De Vuyst, Charissa Kam, Cameron McKinzie, Charles Esther

    Medication Utilization and Lung Function Changes